TY - JOUR
T1 - Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA)
T2 - a multinational prospective cohort study
AU - Stewardson, Andrew J.
AU - Marimuthu, Kalisvar
AU - Sengupta, Sharmila
AU - Allignol, Arthur
AU - El-Bouseary, Maisra
AU - Carvalho, Maria J.
AU - Hassan, Brekhna
AU - Delgado-Ramirez, Monica A.
AU - Arora, Anita
AU - Bagga, Ruchika
AU - Owusu-Ofori, Alex K.
AU - Ovosi, Joseph O.
AU - Aliyu, Shamsudin
AU - Saad, Hala
AU - Kanj, Souha S.
AU - Khanal, Basudha
AU - Bhattarai, Balkrishna
AU - Saha, Samir K.
AU - Uddin, Jamal
AU - Barman, Purabi
AU - Sharma, Latika
AU - El-Banna, Tarek
AU - Zahra, Rabaab
AU - Saleemi, Mansab Ali
AU - Kaur, Amarjeet
AU - Iregbu, Kenneth
AU - Uwaezuoke, Nkolika SC
AU - Abi Hanna, Pierre
AU - Feghali, Rita
AU - Correa, Ana L.
AU - Munera, Maria I.
AU - Le, Thi Anh Thu
AU - Tran, Thi Thanh Nga
AU - Phukan, Chimanjita
AU - Phukan, Chiranjita
AU - Valderrama-Beltrán, Sandra L.
AU - Alvarez-Moreno, Carlos
AU - Walsh, Timothy R.
AU - Harbarth, Stephan
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/6
Y1 - 2019/6
N2 - Background: Low-income and middle-income countries (LMICs)are under-represented in reports on the burden of antimicrobial resistance. We aimed to quantify the clinical effect of carbapenem resistance on mortality and length of hospital stay among inpatients in LMICs with a bloodstream infection due to Enterobacteriaceae. Methods: The PANORAMA study was a multinational prospective cohort study at tertiary hospitals in Bangladesh, Colombia, Egypt, Ghana, India, Lebanon, Nepal, Nigeria, Pakistan, and Vietnam, recruiting consecutively diagnosed patients with carbapenem-susceptible Enterobacteriaceae (CSE)and carbapenem-resistant Entero-bacteriaceae (CRE)bloodstream infections. We excluded patients who had previously been enrolled in the study and those not treated with curative intent at the time of bloodstream infection onset. There were no age restrictions. Central laboratories in India and the UK did confirmatory testing and molecular characterisation, including strain typing. We applied proportional subdistribution hazard models with inverse probability weighting to estimate the effect of carbapenem resistance on probability of discharge alive and in-hospital death, and multistate modelling for excess length of stay in hospital. All patients were included in the analysis. Findings: Between Aug 1, 2014, and June 30, 2015, we recruited 297 patients from 16 sites in ten countries: 174 with CSE bloodstream infection and 123 with CRE bloodstream infection. Median age was 46 years (IQR 15–61). Crude mortality was 20% (35 of 174 patients)for patients with CSE bloodstream infection and 35% (43 of 123 patients)for patients with CRE bloodstream infection. Carbapenem resistance was associated with an increased length of hospital stay (3·7 days, 95% CI 0·3–6·9), increased probability of in-hospital mortality (adjusted subdistribution hazard ratio 1·75, 95% CI 1·04–2·94), and decreased probability of discharge alive (0·61, 0·45–0·83). Multilocus sequence typing showed various clades, with marginal overlap between strains in the CRE and CSE clades. Interpretation: Carbapenem resistance is associated with increased length of hospital stay and mortality in patients with bloodstream infections in LMICs. These data will inform global estimates of the burden of antimicrobial resistance and reinforce the need for better strategies to prevent, diagnose, and treat CRE infections in LMICs. Funding: bioMérieux.
AB - Background: Low-income and middle-income countries (LMICs)are under-represented in reports on the burden of antimicrobial resistance. We aimed to quantify the clinical effect of carbapenem resistance on mortality and length of hospital stay among inpatients in LMICs with a bloodstream infection due to Enterobacteriaceae. Methods: The PANORAMA study was a multinational prospective cohort study at tertiary hospitals in Bangladesh, Colombia, Egypt, Ghana, India, Lebanon, Nepal, Nigeria, Pakistan, and Vietnam, recruiting consecutively diagnosed patients with carbapenem-susceptible Enterobacteriaceae (CSE)and carbapenem-resistant Entero-bacteriaceae (CRE)bloodstream infections. We excluded patients who had previously been enrolled in the study and those not treated with curative intent at the time of bloodstream infection onset. There were no age restrictions. Central laboratories in India and the UK did confirmatory testing and molecular characterisation, including strain typing. We applied proportional subdistribution hazard models with inverse probability weighting to estimate the effect of carbapenem resistance on probability of discharge alive and in-hospital death, and multistate modelling for excess length of stay in hospital. All patients were included in the analysis. Findings: Between Aug 1, 2014, and June 30, 2015, we recruited 297 patients from 16 sites in ten countries: 174 with CSE bloodstream infection and 123 with CRE bloodstream infection. Median age was 46 years (IQR 15–61). Crude mortality was 20% (35 of 174 patients)for patients with CSE bloodstream infection and 35% (43 of 123 patients)for patients with CRE bloodstream infection. Carbapenem resistance was associated with an increased length of hospital stay (3·7 days, 95% CI 0·3–6·9), increased probability of in-hospital mortality (adjusted subdistribution hazard ratio 1·75, 95% CI 1·04–2·94), and decreased probability of discharge alive (0·61, 0·45–0·83). Multilocus sequence typing showed various clades, with marginal overlap between strains in the CRE and CSE clades. Interpretation: Carbapenem resistance is associated with increased length of hospital stay and mortality in patients with bloodstream infections in LMICs. These data will inform global estimates of the burden of antimicrobial resistance and reinforce the need for better strategies to prevent, diagnose, and treat CRE infections in LMICs. Funding: bioMérieux.
UR - http://www.scopus.com/inward/record.url?scp=85065887931&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30792-8
DO - 10.1016/S1473-3099(18)30792-8
M3 - Article
C2 - 31047852
AN - SCOPUS:85065887931
SN - 1473-3099
VL - 19
SP - 601
EP - 610
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 6
ER -